BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 16213741)

  • 1. Allogeneic hematopoietic cell transplantation (HCT) following reduced-intensity conditioning in patients with acute leukemias.
    Niederwieser D; Gentilini C; Hegenbart U; Lange T; Becker C; Wang SY; Bartsch K; Pönisch W; Raida M; Al-Ali H
    Crit Rev Oncol Hematol; 2005 Nov; 56(2):275-81. PubMed ID: 16213741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias: 'what is the best recipe?'.
    Kassim AA; Chinratanalab W; Ferrara JL; Mineishi S
    Bone Marrow Transplant; 2005 Oct; 36(7):565-74. PubMed ID: 15995714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
    Huisman C; Meijer E; Petersen EJ; Lokhorst HM; Verdonck LF
    Biol Blood Marrow Transplant; 2008 Feb; 14(2):181-6. PubMed ID: 18215778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can reduced-intensity allogeneic transplantation cure older adults with AML?
    Storb R
    Best Pract Res Clin Haematol; 2007 Mar; 20(1):85-90. PubMed ID: 17336258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months.
    Eapen M; Rubinstein P; Zhang MJ; Camitta BM; Stevens C; Cairo MS; Davies SM; Doyle JJ; Kurtzberg J; Pulsipher MA; Ortega JJ; Scaradavou A; Horowitz MM; Wagner JE
    J Clin Oncol; 2006 Jan; 24(1):145-51. PubMed ID: 16382124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced intensity conditioning (RIC) haematopoietic cell transplants in elderly patients with AML.
    Niederwieser D; Lange T; Cross M; Basara N; Al-Ali H
    Best Pract Res Clin Haematol; 2006; 19(4):825-38. PubMed ID: 16997186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia.
    Valcárcel D; Martino R
    Curr Opin Oncol; 2007 Nov; 19(6):660-6. PubMed ID: 17906468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen.
    Maruyama D; Fukuda T; Kato R; Yamasaki S; Usui E; Morita-Hoshi Y; Kim SW; Mori S; Heike Y; Makimoto A; Tajima K; Tanosaki R; Tobinai K; Takaue Y
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):932-41. PubMed ID: 17640597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors.
    Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L
    Haematologica; 2008 Feb; 93(2):265-72. PubMed ID: 18245651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience.
    Arellano ML; Langston A; Winton E; Flowers CR; Waller EK
    Biol Blood Marrow Transplant; 2007 Jan; 13(1):116-23. PubMed ID: 17222760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation.
    Loren AW; Porter DL
    Bone Marrow Transplant; 2008 Mar; 41(5):483-93. PubMed ID: 18026156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML.
    Craddock CF
    Bone Marrow Transplant; 2008 Mar; 41(5):415-23. PubMed ID: 18209726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.
    Small TN; Young JW; Castro-Malaspina H; Prockop S; Wilton A; Heller G; Boulad F; Chiu M; Hsu K; Jakubowski A; Kernan NA; Perales MA; O'Reilly RJ; Papadopoulos EB
    Biol Blood Marrow Transplant; 2007 Feb; 13(2):235-44. PubMed ID: 17241929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation.
    Lutz C; Massenkeil G; Nagy M; Neuburger S; Tamm I; Rosen O; Dörken B; Arnold R
    Bone Marrow Transplant; 2008 May; 41(9):805-12. PubMed ID: 18195682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bone marrow transplantation in the treatment of acute leukemias].
    Moiseev SI; Ganapiev AA; Abdulkadyrov KM
    Ter Arkh; 1996; 68(12):8-10. PubMed ID: 9054052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation.
    Mohty M; Labopin M; Tabrizzi R; Theorin N; Fauser AA; Rambaldi A; Maertens J; Slavin S; Majolino I; Nagler A; Blaise D; Rocha V; ;
    Haematologica; 2008 Feb; 93(2):303-6. PubMed ID: 18245655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning.
    Grigg AP; Gibson J; Bardy PG; Reynolds J; Shuttleworth P; Koelmeyer RL; Szer J; Roberts AW; To LB; Kennedy G; Bradstock KF
    Biol Blood Marrow Transplant; 2007 May; 13(5):560-7. PubMed ID: 17448915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up.
    Oyekunle AA; Kröger N; Zabelina T; Ayuk F; Schieder H; Renges H; Fehse N; Waschke O; Fehse B; Kabisch H; Zander AR
    Bone Marrow Transplant; 2006 Jan; 37(1):45-50. PubMed ID: 16258531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.